Add-on recaticimab cuts bad cholesterol in non-FH, mixed hyperlipidaemia patients
05 Dec 2023
In the phase III REMAIN-2 trial, add-on recaticimab – a novel, long-acting anti-PCSK9 monoclonal antibody (mAb) – led to reductions in bad cholesterol and other lipids in patients with non-familial hypercholesterolaemia (non-FH) and mixed hyperlipidaemia inadequately controlled on background statin therapy.
Holistic skincare routine
linked to treatment outcomes
01 Dec 2023;
Professor Goh Chee-Leok, of the National Skin Centre, Singapore, discusses the importance of physician-led treatment and maintenance of skin conditions in patients with typical skin disease.
Sign Out
